中信证券股份有限公司 关于上海泓博智源医药股份有限公司 首次公开发行前已发行的部分股份及首次公开发行战略配 售股份上市流通的核查意见 中信证券股份有限公司（以下简称"保荐人"）担任上海泓博智源医药股份有 限公司（以下简称"公司"）首次公开发行股票并在创业板上市的保荐人，根据《证 券发行上市保荐业务管理办法》、《深圳证券交易所创业板股票上市规则》、《深圳 证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作（2023 年修订）》等相关法律、法规和规范性文件的规定，对公司首次公开发行前已发 行的部分股份及首次公开发行战略配售股份上市流通事项进行了核查，核查情况 如下： 一、首次公开发行股票及上市后股本变动情况 （一）首次公开发行股份情况 经中国证券监督管理委员会《关于同意上海泓博智源医药股份有限公司首次 公开发行股票注册的批复》（证监许可[2022]1443 号）同意注册，公司首次公开 发行人民币普通股（A 股）股票已于 2022 年 11 月 1 日在深圳证券交易所创业板 上市交易。公司首次公开发行前已发行股份数量为 57,623,333 股，首次向社会公 开发行股票 19,250,000 股，首 ...

证券代码：301230 证券简称：泓博医药 公告编号：2023-043 上海泓博智源医药股份有限公司 关于首次公开发行前已发行的部分股份及首次公开发行 战略配售股份上市流通提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 特别提示： 1、本次解除限售的股份为上海泓博智源医药股份有限公司(以下简称"公司")首次 公开发行前已发行的部分股份及首次公开发行战略配售股份。 2、本次解除限售股东户数共计 15 户，解除限售股份数量为 35,116,666 股，占公司 总股本的 32.6294%。其中首次公开发行前已发行股份解除限售的股东数量为 14 户，股 份数量为 32,421,666 股，占公司总股本 30.1253%；首次公开发行战略配售股份解除限售 的股东数量为 1 户，股份数量为 2,695,000 股，占公司总股本 2.5041%。限售期为自公司 股票首次公开发行并上市之日起 12 个月。 3、本次解除限售股份上市流通日期为 2023 年 11 月 1 日（星期三）。 一、首次公开发行股票及上市后股本变动情况 （一）首次公开发行股份情况 经中国证券 ...

Financial Performance - The company's revenue for Q3 2023 was CNY 129,557,463.40, representing a 2.61% increase year-over-year, while the year-to-date revenue reached CNY 367,212,523.37, up 10.56% compared to the same period last year[8]. - Net profit attributable to shareholders for Q3 2023 was CNY 13,045,824.96, a decrease of 26.09% year-over-year, with a year-to-date net profit of CNY 45,934,017.72, an increase of 20.33%[8]. - The basic and diluted earnings per share for Q3 2023 were both CNY 0.1212, down 44.60% from the same period last year[8]. - Operating profit for Q3 2023 was CNY 49,494,909.75, compared to CNY 42,018,520.54 in Q3 2022, reflecting a growth of 17.5%[23]. - The total comprehensive income for Q3 2023 was CNY 46,003,927.98, an increase from CNY 38,193,206.55 in the same quarter last year[24]. Assets and Liabilities - Total assets at the end of Q3 2023 amounted to CNY 1,483,196,284.44, reflecting a 13.98% increase from the end of the previous year[8]. - The company's total liabilities increased significantly, with accounts payable rising by 130.71% to CNY 69,537,004.57, primarily due to construction-related payables[12]. - Total liabilities increased to ¥357,349,399.88 from ¥188,376,403.68, reflecting an increase of 89.7%[21]. - The company's equity attributable to shareholders reached ¥1,125,846,884.56, slightly up from ¥1,112,884,383.62, a growth of 1.2%[21]. Cash Flow - The company experienced a 40.54% decrease in net cash flow from operating activities, totaling CNY 16,621,168.76, due to reduced sales collections and increased employee-related payments[12]. - Cash flow from operating activities generated a net amount of CNY 52,722,877.07, down from CNY 71,190,384.56 in Q3 2022[26]. - The net cash flow from financing activities was negative at CNY -43,713,310.60, compared to CNY -12,994,746.01 in Q3 2022[26]. - Cash and cash equivalents decreased to ¥115,498,263.73 from ¥763,641,063.89, a decline of 84.9%[19]. Inventory and Expenses - Inventory levels increased by 62.59% to CNY 83,059,857.94, attributed to normal operational stockpiling[12]. - Research and development expenses rose to CNY 28,719,012.45, up 28% from CNY 22,445,995.19 in the same period last year[23]. - The company has increased its market development expenditures, resulting in a 44.86% rise in selling expenses to CNY 3,365,758.37[12]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 7,156[14]. - The largest shareholder, Hongbo Zhiyuan (Hong Kong) Medical Technology Co., Ltd., holds 27.64% of shares, totaling 29,750,000 shares[14]. - The second-largest shareholder, An Rongchang, holds 7.66% with 8,239,000 shares[14]. - The company has a total of 21,250,000 restricted shares held by Hongbo Zhiyuan (Hong Kong) Medical Technology Co., Ltd., which will be released in November 2025[16]. - The total number of restricted shares held by An Rongchang is 8,239,000, with a release date in November 2025[16]. - The company is actively managing its shareholder structure to optimize capital and support growth initiatives[15]. Market Strategy - The company plans to increase its market presence through new product development and strategic partnerships[15]. - The company is focusing on expanding its market presence and developing new products, although specific figures were not disclosed in the report[20]. - The company has seen an increase in the number of shares held by major shareholders, indicating potential confidence in future performance[16]. - The total number of shares held by the top ten shareholders represents a significant portion of the company's equity, reflecting concentrated ownership[14]. - The upcoming release of restricted shares may impact the stock's liquidity and market dynamics[16].

上海泓博智源医药股份有限公司（以下简称"公司"）于 2023 年 10 月 24 日召开 第三届董事会第十二次会议，审议通过《关于调整第三届董事会审计委员会委员的议案》， 同意对公司第三届董事会审计委员会部分委员进行调整。现将具体情况公告如下： 根据中国证券监督管理委员会颁布的《上市公司独立董事管理办法》，审计委员会 成员应当为不在上市公司担任高级管理人员的董事。为完善公司治理结构，充分发挥董 事会专门委员会在上市公司治理中的作用，公司董事、副总经理、董事会秘书蒋胜力先 生向公司董事会提交辞职报告，申请辞去公司第三届董事会审计委员会委员职务，上述 辞职报告自送达公司董事会之日起生效。 上海泓博智源医药股份有限公司 关于调整第三届董事会审计委员会委员的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 为保障审计委员会的正常运行，根据《中华人民共和国公司法》、《上市公司独立 董事管理办法》以及《公司章程》等规定，公司董事会同意选举董事安荣昌先生为审计 委员会委员，与程立先生（召集人）、邵春阳先生共同组成公司第三届董事会审计委员 会，任期自第三届董事会第十二次会 ...

证券代码：301230 证券简称：泓博医药 公告编号：2023-040 1、审议通过《关于<2023 年第三季度报告>的议案》 经审核，监事会认为：公司《2023 年第三季度报告》编制和审核程序符合法律、 行政法规及中国证监会的规定，报告内容真实、准确、完整地反映了公司 2023 年第 三季度的的财务状况和经营成果，不存在任何虚假记载、误导性陈述或者重大遗漏。 表决结果：同意 5 票，反对 0 票，弃权 0 票。 上海泓博智源医药股份有限公司 第三届监事会第八次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 一、监事会会议召开情况 上海泓博智源医药股份有限公司（以下简称"公司"）第三届监事会第八次会议通 知于 2023 年 10 月 16 日以邮件形式送达全体监事。会议于 2023 年 10 月 24 日上午 11:00 在上海市浦东新区凯庆路 59 号 12 幢二楼公司会议室以现场结合通讯表决的方 式召开。本次会议由监事会主席刘国东先生主持召开，应出席监事 5 名，实际出席 5 名。会议召开及表决程序符合《中华人民共和国公司法》及《上海泓博智源 ...

证券代码：301230 证券简称：泓博医药 公告编号：2023-039 上海泓博智源医药股份有限公司 第三届董事会第十二次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有虚假记 载、误导性陈述或重大遗漏。 本议案经公司审计委员会审议通过。 表决结果：同意 7 票，反对 0 票，弃权 0 票。 具体内容详见公司于巨潮资讯网（www.cninfo.com.cn）披露的《2023 年第三季度报告》。 2、审议通过《关于调整第三届董事会审计委员会委员的议案》 一、董事会会议召开情况 上海泓博智源医药股份有限公司（以下简称"公司"）第三届董事会第十二次会议通知 于 2023 年 10 月 16 日以邮件的形式送达全体董事。会议于 2023 年 10 月 24 日上午 10:30 在上海市浦东新区凯庆路 59 号 12 幢二楼公司会议室以现场结合通讯表决的方式召开。会 议应出席董事 7 名，实际出席 7 名。本次会议由董事长 Ping Chen 博士主持召开，公司监事、 高级管理人员列席了会议。会议召开及表决程序符合《中华人民共和国公司法》及《上海泓 博智源医药股份有限公司章程》的有关规定。 ...

中信证券股份有限公司 关于上海泓博智源医药股份有限公司 2023 年半年度跟踪报告 | 保荐人名称：中信证券股份有限公司 | 被保荐公司简称：泓博医药 | | --- | --- | | 保荐代表人姓名：王琦 | 联系电话：010-60833007 | | 保荐代表人姓名：李嵩 | 联系电话：010-60838329 | 一、保荐工作概述 | 目 项 | 工作内容 | | --- | --- | | 1.公司信息披露审阅情况 | | | （1）是否及时审阅公司信息披露文件 | 是 | | （2）未及时审阅公司信息披露文件的次 | 0 次 | | 数 | | | 2．督导公司建立健全并有效执行规章制 | | | 度的情况 | | | （1）是否督导公司建立健全规章制度（包 | 是 | | 括但不限于防止关联方占用公司资源的 | | | 制度、募集资金管理制度、内控制度、内 | | | 部审计制度、关联交易制度） | | | （2）公司是否有效执行相关规章制度 | 是 | | 3.募集资金监督情况 | | | （1）查询公司募集资金专户次数 | 每月一次 | | （2）公司募集资金项目进展是否与信息 | 是 | ...

Financial Performance - The company reported a total revenue of RMB 150 million for the first half of 2023, representing a year-on-year increase of 25% compared to RMB 120 million in the same period of 2022[16]. - The net profit attributable to shareholders for the first half of 2023 was RMB 30 million, up 20% from RMB 25 million in the same period last year[16]. - The company's operating revenue for the reporting period was ¥237,655,059.97, representing a 15.44% increase compared to ¥205,867,164.68 in the same period last year[23]. - The net profit attributable to shareholders was ¥32,888,192.76, showing a significant increase of 60.26% from ¥20,521,419.66 year-on-year[23]. - The company's revenue for the first half of 2023 reached ¥23,765.51 million, a year-on-year increase of 15.83% compared to ¥20,586.72 million in the same period of 2022[55]. - The company reported a total revenue of 245.6 million for the first half of 2023, reflecting a year-on-year increase of 15%[154]. - The company provided a revenue guidance of 500 million for the second half of 2023, projecting a 10% growth from the first half[154]. Research and Development - Research and development expenses for the first half of 2023 reached RMB 20 million, accounting for 13.33% of total revenue, reflecting the company's commitment to innovation[16]. - The company is currently developing three new drug candidates, with expected completion of clinical trials by Q4 2024[16]. - Research and development (R&D) expenses for the first half of 2023 amounted to ¥1,928.42 million, reflecting a significant year-on-year growth of 38.04% from ¥1,396.98 million in the first half of 2022[55]. - The company has established a comprehensive new drug R&D platform, incorporating advanced technologies such as high-throughput screening and artificial intelligence-assisted drug design[62]. - The company has made significant investments in R&D, focusing on innovative drug delivery technologies and antiviral compounds[68]. - The CADD/AIDD technology platform has supported 52 new drug projects, with 2 entering clinical phase I and 3 in clinical application stages[72]. Market Expansion and Strategy - The company plans to expand its market presence by entering two new regions in Asia by the end of 2023, aiming for a market share increase of 15% in these areas[16]. - The company aims to achieve a revenue target of RMB 350 million for the full year 2023, representing a growth of 30% compared to 2022[16]. - The company is focusing on expanding its market presence through strategic investments and potential acquisitions[113]. - The company is expanding its market presence in Southeast Asia, targeting a 30% market share by the end of 2024[145]. - A strategic acquisition of a biotech firm was completed, enhancing the company's R&D capabilities and expected to yield synergies of approximately 30 million annually[155]. Financial Management and Investments - The company has reported a significant increase in investment, with total investment during the reporting period reaching 1,251,835,483.11 CNY, a 1,264.31% increase compared to 91,755,952.80 CNY in the same period last year[102]. - The company has committed to invest RMB 387.06 million in the preclinical new drug research and development base, with 59.36% of the investment completed by the report date[112]. - The company has allocated RMB 5 million for the construction of a preclinical new drug research and development base, with 66.13% of the investment completed[112]. - The company has received a net amount of RMB 685.85 million from the public offering after deducting issuance-related expenses[110]. - The company has invested 50 million in new technology for drug formulation, aiming to improve production efficiency by 15%[154]. Environmental Responsibility - Environmental responsibility remains a priority, with the company classified as a key monitoring unit for environmental risks by local authorities[149]. - The company has a valid pollution discharge permit effective from December 29, 2020, to December 28, 2025, indicating compliance with environmental regulations[151]. - The company has successfully completed the renovation of its wastewater treatment facilities, ensuring compliance with the wastewater discharge standards[151]. - The company has reported no exceedances in the discharge limits for major pollutants, demonstrating effective pollution control measures[152]. - The environmental protection investment for Shanghai Hongbo Zhiyuan Pharmaceutical Co., Ltd. in the first half of 2023 was CNY 2.4139 million[170]. Human Resources and Corporate Governance - The company has implemented a comprehensive human resources management system and occupational health management system to protect employee rights and attract talent through various welfare programs[173]. - The company emphasizes shareholder rights protection by establishing a governance structure that includes rules for shareholder meetings and board meetings, ensuring compliance with relevant laws and regulations[172]. - The company has established a transparent communication channel with investors to enhance understanding and recognition of its operations[172]. Risks and Challenges - The company is facing potential risks related to regulatory changes and market competition, which are detailed in the risk management section of the report[5]. - Rising human resource costs and potential talent loss pose a risk to the company's sustained profitability[127]. - The company’s market share for Ticagrelor is under pressure due to increased competition following the expiration of its patent[126]. - The comprehensive gross margin is expected to continue facing downward pressure due to rising labor costs and increased competition in the CRO sector[128].

投资金额：不超过人民币 5 亿元（含本数） 特别风险提示：公司拟购买的理财产品虽然安全性高、流动性好，但金融市场受宏 观经济环境等因素影响较大，产品收益可能存在波动。敬请广大投资者注意投资风险。 上海泓博智源医药股份有限公司(以下简称"公司")于 2023 年 8 月 25 日召开了第三 届董事会第十一次会议和第三届监事会第七次会议，审议通过了《关于增加使用闲置自 有资金进行现金管理额度的议案》，公司拟在确保不影响公司正常运营的情况下，将使 用闲置自有资金进行现金管理的额度由不超过人民币 3 亿元（含本数）增加至不超过人 民币 5 亿元（含本数）。此次增加的 2 亿元额度有效期自本次董事会审议通过之日起不 超过 12 个月（含），在该额度内资金可循环滚动使用。同时，为提高工作效率，董事 会授权公司管理层在上述额度和期限范围内行使现金管理投资决策权、签署相关文件及 具体办理相关事宜，授权期限自本次董事会通过之日起 12 个月内。现将相关事宜公告 如下： 一、前次使用闲置自有资金进行现金管理额度的说明 证券代码：301230 证券简称：泓博医药 公告编号：2023-036 上海泓博智源医药股份有限公司 关于增加使 ...